PD-1 SIGNAL INHIBITOR COMBINATION THERAPY

Title:

PD-1 SIGNAL INHIBITOR COMBINATION THERAPY

Document Type and Number:

WIPO Patent Application WO/2017/099034

Kind Code:

A1

Abstract:

Provided is a novel treatment strategy for anti-PD-1 antibody treatment. A pharmaceutical composition including at least one substance selected from the group consisting of (i)-(iii) below, administered before, after, or simultaneously with administration of a PD-1 signal inhibitor. (i) ROS generators and substances that control downstream signals thereof, (ii) substances exhibiting an uncoupling effect and substances that control downstream signals thereof, and (iii) amino acids

More Like This:

JP2019521191	Methods and compositions for anti-cancer therapies targeting MENA protein isoform kinases
JP2007512223	Treatment of asthma or chronic obstructive pulmonary disease with a combination of dehydroepiandrosterone or sulfate dehydroepiandrosterone and a PDE-4 inhibitor
WO/2021/076565	METHOD OF NORMALIZING THE NEUTROPHIL TO LYMPHOCYTE RATIO IN CANCER PATIENTS WITH A SELECTIVE GLUCOCORTICOID RECEPTOR ANTAGONIST

Inventors:

HONJO TASUKU (JP)
CHAMOTO KENJI (JP)
FAGARASAN SIDONIA (JP)

Application Number:

PCT/JP2016/086045

Publication Date:

June 15, 2017

Filing Date:

December 05, 2016

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV KYOTO (JP)

International Classes:

A61K45/06; A61K31/045; A61K31/06; A61K31/122; A61K31/275; A61K31/327; A61K31/53; A61K31/661; A61K39/395; A61P31/00; A61P31/04; A61P31/06; A61P31/08; A61P31/10; A61P31/12; A61P31/14; A61P31/16; A61P31/18; A61P31/20; A61P31/22; A61P33/00; A61P33/02; A61P33/04; A61P33/06; A61P33/10; A61P33/12; A61P35/00; A61P35/02; A61P43/00

Domestic Patent References:

WO2015095404A2

2015-06-25

Foreign References:

JP2012144498A	2012-08-02
JP2015522048A	2015-08-03
JP2003509447A	2003-03-11
JP2007191424A	2007-08-02
JP2005519926A	2005-07-07
JP2010180244A	2010-08-19

Other References:

KWAN, H.T. ET AL.: "AMPK Activators Suppress Cervical Cancer Cell Growth through Inhibition of DVL3 Mediated Wnt/beta-catenin Signaling Activity", PLOSONE, vol. 8, no. 1, 2 January 2013 (2013-01-02), pages 1 - 10, XP055390973
TURAN, AGHAYEV ET AL.: "FOXOs suppress lipid peroxidation to promote AML progression and chemotherapy resistance.", BLOOD, vol. 126, no. 23, 3 December 2015 (2015-12-03), pages 1861, XP055508843, [retrieved on 20170202]
LI, CHIA-WEI ET AL.: "Glycosylation and stabilization of programmed death ligand-1 suppresses T- cell activity.", NATURE COMMUNICATIONS, vol. 7, no. 12632, 30 August 2016 (2016-08-30), pages 1 - 11, XP055371693

Attorney, Agent or Firm:

MAYAMA, Setsuko et al. (JP)

Download PDF:

View/Download PDF PDF Help

Previous Patent: FLUID STERILIZATION DEVICE

Next Patent: HEADLIGHT FOR VEHICLE